Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Terminated 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1PRETEXT I Hepatoblastoma 1Myelodysplastic Syndromes 1Malignant mesenchymal tumor 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Ganglioneuroblastoma 1Burkitt Lymphoma 1

Interventions

Radiotherapy 11pembrolizumab 10Nivolumab 10Doxorubicin 10Magnetic Resonance Spectroscopy 9Specimen Handling 8Ipilimumab 7Cyclophosphamide 7Biopsy 7X-Rays 6Radiation 5Phantoms, Imaging 5Ifosfamide 5talimogene laherparepvec 4cabozantinib 4Nuclear Medicine Department, Hospital 4Irinotecan 4tazemetostat 3selpercatinib 3pazopanib 3liposomal doxorubicin 3Temozolomide 3Etoposide 3ulixertinib 2tislelizumab 2tipifarnib 2palbociclib 2larotrectinib 2ivosidenib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sarcoma × Dexrazoxane × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡